Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Official title: A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2025-08-28
Completion Date
2029-06
Last Updated
2026-04-22
Healthy Volunteers
No
Interventions
ADX-038 Dose Level 2
siRNA duplex oligonucleotide
ADX-038 Dose Level 1
siRNA duplex oligonucleotide
Locations (25)
ADARx Clinical Site
Doral, Florida, United States
ADARx Clinical Site
Miami, Florida, United States
ADARx Clinical Site
Pembroke Pines, Florida, United States
ADARx Clinical Site
Iowa City, Iowa, United States
ADARx Clinical Site
Shreveport, Louisiana, United States
ADARx Clinical Site
Shelby, Michigan, United States
ADARx Clinical Site
Great Neck, New York, United States
ADARx Clinical Site
Columbus, Ohio, United States
ADARx Clinical Site
Dakota Dunes, South Dakota, United States
ADARx Clinical Site
Dallas, Texas, United States
ADARx Clinical Site
Houston, Texas, United States
ADARx Clinical Site
Wollongong, New South Wales, Australia
ADARx Clinical Site
Sydney, Australia
ADARx Clinical Site
Woolloongabba, Australia
ADARx Clinical Site
Hong Kong, Hong Kong
ADARx Clinical Site
Shatin, Hong Kong
ADARx Clinical Site
Cheonan, South Korea
ADARx Clinical Site
Daegu, South Korea
ADARx Clinical Site
Gyeonggi-do, South Korea
ADARx Clinical Site
Seoul, South Korea
ADARx Clinical Site
Seoul, South Korea
ADARx Clinical Site
Seoul, South Korea
ADARx Clinical Site
Seoul, South Korea
ADARx Clinical Site
Madrid, Spain
ADARx Clinical Site
Newcastle upon Tyne, United Kingdom